Ventyx Biosciences (VTYX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VTYX Ventyx Biosciences

Watchlist

2.250
-0.060-2.60%

Close Jan 24 16:00 ET

2.220
-0.030-1.33%

Post 20:01 ET

159.10MMarket Cap-0.96P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating
Moomoo NewsJan 14 12:31 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciencesto Neutral
BenzingaJan 14 12:29 ET
Ventyx Announces Phase 2 Trials For VTX2735, VTX3232; Obesity Data Expected H2 2025, Parkinson's Data H1 2025; $252.9M Funding Extends To H2 2026
BenzingaJan 14 08:15 ET
Ventyx Biosciences Highlights Its 2025 Pipeline Strategy
TipRanksJan 14 08:11 ET
Express News | Ventyx Biosciences: Topline Data From Ongoing Phase 2 Biomarker Trial of Vtx3232 in Participants With Early Parkinson's Disease Expected in H1 2025
ReutersJan 14 08:00 ET
Express News | Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor Portfolio
ReutersJan 14 08:00 ET

Comments

Tonyco

Nov 29, 2024 19:20

Columns Pay me

Here have some gifts, my weekend work so far:
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...

Jaguar8

Oct 15, 2024 08:03

NEWS

$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...